Association between sodium-glucose cotransporter 2 inhibitors and lower extremity amputation among patients with type 2 diabetes

JAMA Internal Medicine

Volumn 178, Issue 9, 2018, Pages 1242-1248

  Chang, Hsien Yen ^a   Singh, Sonal ^b   Mansour, Omar ^a   Baksh, Sheriza ^a   Caleb Alexander, G ^a,c  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF MASSACHUSETTS   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BILE ACID SEQUESTRANT; CALCIUM CHANNEL BLOCKING AGENT; CARBONATE DEHYDRATASE INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; FIBRIC ACID DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT; METFORMIN; NICOTINIC ACID; POTASSIUM SPARING DIURETIC AGENT; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA; THIAZIDE DIURETIC AGENT; CANAGLIFLOZIN; GLUCAGON LIKE PEPTIDE 1;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CRITICAL LIMB ISCHEMIA; DIABETIC PATIENT; DISEASE ASSOCIATION; DRUG USE; FEMALE; HEALTH INSURANCE; HUMAN; ICD-9-CM; LEG AMPUTATION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOMYELITIS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POPULATION RESEARCH; PRIORITY JOURNAL; PROPENSITY SCORE; RETROSPECTIVE STUDY; ULCER; ADVERSE EVENT; AMPUTATION; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPLICATION; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEALTH SURVEY; INCIDENCE; LOWER LIMB; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; UNITED STATES;

AMPUTATION; BLOOD GLUCOSE; CANAGLIFLOZIN; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INCIDENCE; LOWER EXTREMITY; MALE; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; POPULATION SURVEILLANCE; PROPENSITY SCORE; RETROSPECTIVE STUDIES; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; UNITED STATES;

EID: 85053008994     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2018.3034     Document Type: Article

References (29)

1. Centers for Disease Controland Prevention. Na-tional Diabetes Statistics Report, 2017. Atlanta, GA: Centers for Disease Control and Prevention, US Dept of Health and Human Services; 2017.
2. US Food and Drug Administration. FDA confirms increased risk of leg and foot amputations with the diabetes medicine canag lifloz in (Invokana, Invokamet, Invokamet XR). https://www.fda.gov /downloads/Drugs/DrugSafety/UCM558427.pdf. Updated May 16, 2017. Accessed October 17, 2017.
3. Fulcher G, Matthews DR, Perkovic V, et al. Efficacy and safety of canag liflozinusedincon junction with sulf on ylureain patients with type2 diabete smellitus: controlled trial. Diabetes Ther. 2015;6(3):289-302. doi:10.1007/s13300-015-0117-z
4. Fulcher G, Matthews DR, Perkovic V, et al; CANVAS Trial Collaborative Group. Efficacy and safety of can aglifloz in when use dinconjunction with in cretin-mimetic therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2016;18(1):82-91.doi:10.1111/dom.12589
5. Neal B, Perkovic V, de Zeeuw D, et al; CANVAS Trial Collaborative Group. Efficacy and safety of canagli-flozin, aninhibitor of sodium-glucosecotrans porter 2, when used in conjunction with in sulintherapy in patients with type 2 diabetes. Diabetes Care. 2015;38 (3):403-411.doi:10.2337/dc14-1237
6. Neal B, Perkovic V, Mahaffey KW, et al; CANVAS Program Collaborative Group. Can agliflozinand cardio vascular and renalevents in type2 diabetes. N Engl J Med. 2017;377(7):644-657. doi:10.1056/NEJMoa1611925
7. Lee S. Update on SGLT2 inhibitors-newdata release dat the American Diabetes Association. Crit Pathw Cardiol. 2017;16(3):93-95.doi:10.1097/HPC.0000000000000125
8. Liu J, Lee TW, De Fronzo RA. Why do SGLT2 inhibitors inhibit only 30-50% of renalglucose absorptioninhumans? Diabetes. 2012; 61:2199-2204. doi:10.2337/db12-0052
9. Chang CC, Chen YT, Hsu CY, et al. Dipeptidyl peptidase-4inhibitors, peripheralarterial disease, and lower extremityamputationris kind iabeticpatients. Am J Med.2017;130(3):348-355. doi:10.1016/j.amjmed.2016.10.016
10. Newton KM, Wagner EH, Ramsey SD, et al. The use of automated data to identify complications and comorbidities of diabetes: a validation study. J Clin Epidemiol. 1999;52(3):199-207. doi:10.1016/S0895 -4356(98)00161-9
11. Bekwelem W, Bengtson LG, Oldenburg NC, et al. Development of administrative data algorithmsto identify patients with criticallimbischemia. Vasc Med. 2014;19(6):483-490. doi:10.1177/1358863X14559589
12. Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Predicting costs with Diabetes Complications Severity Indexin claims data. Am J Manag Care. 2012;18(4):213-219.
13. Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index inclaims data. Am J Manag Care. 2012;18(11):721-726.
14. Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagonlikepeptide1-basedtherapies and risk of hospitalization for acutepan creatitisin type 2 diabetes mellitus: apopulation-basedmatched case-controlstudy. JAMA Intern Med. 2013;173(7):534-539.doi:10.1001/jamainternmed.2013.2720
15. Chang HY, Hsieh CF, Singh S, Tang W, Chiang YT, Huang WF. Anti-diabetic the rapies and the risk of acute pancreatitis: anation wide retrospective cohort study from Taiwan. Pharmaco epidemiol Drug Saf. 2015;24(6):567-575.doi:10.1002/pds.3770
16. Tseng YH, Tsan YT, Chan WC, Sheu WH, Chen PC. Use of anα-glucosidase in hibitor and the riskof colorectal cancer in patients with diabetes: a nationwide, population-based cohort study. Diabetes Care. 2015;38(11):2068-2074. doi:10.2337/dc15-0563
17. Ou SM, Shih CJ, Chao PW, et al. Effects on clinical outcomes of adding dipeptidyl peptidase-4inhibitors versussulf onylureastomet for minther apy in patients with type2 diabetes mellitus. Ann Intern Med. 2015; 163(9):663-672.doi:10.7326/M15-0308
18. Chang HY, Zhou M, Tang W, Alexander GC, Singh S. Risk of gastrointest in albleeding associated with oralanticoagulants: population based retrospective cohortstudy. BMJ. 2015;350:h1585.doi:10.1136/bmj.h1585
19. Casadaban L, Rauscher G, Aklilu M, Villenes D, Freels S, Maker AV. Adjuvant chemotherapy is associated with improved survival in patients with stage II colon cancer. Cancer. 2016;122(21):3277-3287. doi:10.1002/cncr.30181
20. Harder VS, Stuart EA, Anthony JC. Propensity score techniques and the assessment of measured covariate balance to testcausal associations in psychological research. Psychol Methods. 2010;15(3):234-249.doi:10.1037/a0019623
21. Kurth T, Walker AM, Glynn RJ, et al. Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol. 2006;163(3):262-270.doi:10.1093/aje/kwj047
22. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observation alstudies. Multivariate Behav Res. 2011; 46(3):399-424. doi:10.1080/00273171.2011.568786
23. Lin DY, Wei LJ. The robust inference for the Cox proportionalhazards model. J Am Stat Assoc. 1989; 84:1074-1078.doi:10.1080/01621459.1989.10478874
24. Lin DY, Wei LJ, Ying Z. Checking the Coxmodel with cumulatives umsofmarting ale-basedresiduals. Biometrika.1993;80:557-572.doi:10.1093/biomet/80.3.557
25. European Medicines Agency. Pharmacovigilence Risk Assessment Committee (PRAC): PRA Cassess mentreport.http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/SGLT2 _inhibitors_Canagliflozin_20/European_Commission _final_decision/WC500227102.pdf. Published February 9, 2017. Accessed October 23, 2017.
26. US Food and Drug Administration. Sodium-glucosecotransporter-2(SGLT2) inhibitors. https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationfor PatientsandProviders/ucm446852.htm. Updated May 16, 2017. Accessed October 27, 2017.
27. Fadini GP, Avogaro A. SGLT2 in hibitorsand amputations in the USFDA Adverse Event Reporting System. Lancet Diabetes Endocrinol. 2017;5(9):680-681.doi:10.1016/S2213-8587(17)30257-7
28. Yuan Z, De Falco FJ, Ryan PB, et al. Risk of lower extremity amputations in people with type2 diabetes mellitustreated with sodium-glucoseco -transporter-2 in hibitors in the USA: aretrospective cohortstudy. Diabetes Obes Metab. 2018;20(3):582-589.doi:10.1111/dom.13115
29. Hsu CY, Chen YT, Su YW, Chang CC, Huang PH, Lin SJ. Statin therapy reduces future risk of lower-limb amputation in patients with diabetes and peripheral artery disease. J Clin Endocrinol Metab. 2017;102(7):2373-2381. doi:10.1210/jc.2016-3717